Initiatives for Value-Added Products Focused on Medical Safety and Quality of Life

「Through the development of equipment and systems that provide efficient and comfortable services, including contactless specimen identification, automated transport and shorter waiting times through optimized patient guidance using the cloud, for which demand is expected to grow as healthcare providers face labor shortages, the Company will contribute to improving convenience for medical institutions and patients.」

「Revenue from specimen testing equipment for the six months ended ¥290.610 million, down 2.0% year on year. In Japan, sales of blood gas analyzers and electrolyte analyzers recovered slightly, resulting in revenue of ¥162.669 million, up 9.3%. Overseas revenue was ¥127.941 million, down 13.3%, as sales in Asia, particularly the Middle East, fell below the prior-year level.」

「Revenue from specimen testing equipment during the fiscal year was ¥621.770 million, up 3.8% from the previous fiscal year.」

「Through the development of equipment and systems that provide efficient and comfortable services, including contactless specimen identification, automated transport and shorter waiting times through optimized patient guidance using the cloud, for which demand is expected to grow as healthcare providers face labor shortages, the Company will contribute to improving convenience for medical institutions and patients.」

「Revenue from specimen testing equipment during the cumulative second quarter was ¥272.883 million, up 12.9% year on year. Domestic revenue was ¥175.674 million, up 23.0% year on year, mainly because sales of new handheld blood gas analyzers increased.」

「Revenue from specimen testing equipment for the first quarter ended ¥125.301 million, up 15.0% year on year. Revenue in Japan was ¥82.289 million, up 19.8%, and overseas revenue was ¥43.012 million, up 6.8%, mainly because sales of new handheld blood gas analyzers increased in both Japan and overseas.」

「Revenue from specimen testing equipment during the fiscal year was ¥591.011 million, up 5.3% from the previous fiscal year.」

「Revenue from specimen testing equipment during the cumulative third quarter was ¥391.924 million, down 6.7% year on year. Domestic revenue was ¥226.261 million, down 10.8% year on year, due in part to lower sales resulting from the handheld blood gas analyzer being between model changes and unstable procurement of electrolyte analyzers.」

「Revenue from specimen testing equipment during the cumulative second quarter was ¥241.794 million, down 6.0% year on year. Domestic revenue was ¥142.859 million, down 12.1% year on year, due in part to the handheld blood gas analyzer being between model changes and sluggish sales of electrolyte analyzers.」

「Revenue from specimen testing equipment during the fiscal year was ¥561.456 million, down 24.1% year on year. In the previous fiscal year, demand for blood gas analyzers used in emergency testing, including testing related to COVID-19, increased significantly, but this demand normalized in both the domestic and overseas markets during the current fiscal year.」

「Revenue from specimen testing equipment for the first nine months ended ¥419.973 million, down 22.8% year on year. In both Japan and overseas, demand for blood gas analyzers used for emergency testing, including COVID-19 response, had increased sharply in the prior-year period. Reflecting this reversal, revenue in Japan was ¥253.634 million, down 25.9%, and overseas revenue was ¥166.338 million, down 17.7%.」

「Revenue from specimen testing equipment during the cumulative second quarter was ¥257.271 million, down 34.5% year on year. This was due in part to demand for blood gas analyzers used in emergency testing, including testing related to COVID-19, having run its course.」

「Revenue from specimen testing equipment during the cumulative first quarter was ¥106.620 million, down 43.6% year on year. This was due in part to demand for blood gas analyzers used in emergency testing, including testing related to COVID-19, having run its course.」

「Revenue from specimen testing equipment for the fiscal year was ¥740.217 million, up 29.7% from the previous fiscal year.」

「Revenue from specimen testing equipment for the first nine months ended ¥544.338 million, up 45.7% year on year. In Japan, revenue was ¥342.279 million, up 15.3%, mainly because sales of desktop blood gas analyzers and electrolyte analyzers exceeded the prior-year level. Overseas revenue was ¥202.058 million, up 163.5%, mainly because sales of handheld blood gas analyzers used for emergency testing and other applications increased, particularly in emerging markets, amid the impact of COVID-19.」

「Revenue from specimen testing equipment for the first six months ended ¥392.693 million, up 48.0% year on year. In Japan, revenue was ¥231.242 million, up 12.2%, mainly as sales of desktop blood gas analyzers and electrolyte analyzers increased year on year. Overseas revenue was ¥161.451 million, up 172.5%, mainly because sales of handheld blood gas analyzers used for emergency testing and other applications increased amid the impact of COVID-19.」

「Revenue from specimen testing equipment for the first quarter ended ¥189.101 million, up 64.7% year on year. In Japan, revenue was ¥91.421 million, up 12.5%, reflecting increased sales of desktop blood gas analyzers. Overseas revenue was ¥97.680 million, up 191.0%, mainly because sales of handheld blood gas analyzers used for emergency testing and other applications increased amid the impact of COVID-19.」

「Revenue from specimen testing equipment during the fiscal year was ¥570.813 million, down 8.0% year on year. Compared with the previous fiscal year, when sales of the Company’s mainstay blood gas analyzers grew, sales stagnated in both the domestic and overseas markets, resulting in domestic revenue of ¥462.991 million, down 4.9% year on year, and overseas revenue of ¥107.822 million, down 19.3%.」

「Revenue from specimen testing equipment for the cumulative third quarter was ¥373.512 million, down 16.5% year on year. Domestic revenue was ¥296.822 million, down 12.8%, due partly to sluggish sales of higher-end models of the core blood gas analyzers. Overseas revenue was ¥76.690 million, down 28.5%, as sales of both desktop and handheld blood gas analyzers fell below the same period of the previous year.」

「Revenue from specimen testing equipment for the cumulative second quarter was ¥265.376 million, down 17.6% year on year. Domestic revenue was ¥206.137 million, down 15.1%, as sales of blood gas analyzers, which had been strong in the same period of the previous year, showed some stagnation. Overseas revenue was ¥59.238 million, down 25.4%, due partly to delays in sales projects for handheld blood gas analyzers.」

「Revenue from specimen testing equipment for the cumulative first quarter was ¥114.837 million, down 22.8% year on year. Domestic revenue was ¥81.271 million, down 32.2%, as sales of blood gas analyzers, which had been strong in the same period of the previous year, showed some stagnation. Overseas revenue was ¥33.566 million, up 16.3%, as strong sales in the Asian market continued.」

「Revenue from specimen testing equipment during the fiscal year was ¥620.565 million, up 19.9% year on year. Sales of desktop blood gas analyzers remained strong in both the domestic and overseas markets.」

「Revenue from specimen testing equipment for the cumulative third quarter was ¥447.502 million, up 33.6% year on year. Sales of blood gas analyzers remained firm for both desktop and handheld models. Domestic revenue was ¥340.284 million, up 25.4%, and overseas revenue was ¥107.217 million, up 68.8%.」

「Revenue from specimen testing equipment for the cumulative second quarter was ¥322.188 million, up 43.5% year on year. Sales of blood gas analyzers, the core products in the specimen testing equipment field, increased for both desktop and handheld models. Domestic revenue was ¥242.773 million, up 33.2%, while overseas revenue was ¥79.414 million, up 88.1%, as sales of the products increased in emerging markets including Asia and Central and South America.」

「Revenue from specimen testing equipment for the cumulative first quarter was ¥148.660 million, up 40.3% year on year. Sales of blood gas analyzers, the core products in the specimen testing equipment field, increased for both desktop and handheld models. Domestic revenue was ¥119.809 million, up 32.0%, and overseas revenue was ¥28.850 million, up 89.8%.」

「Against this backdrop, and from the standpoint of healthcare financing and QOL, the Company will continue to focus on research and development of specimen testing equipment and healthcare products that are less affected by reimbursement rates, to enable self-care for lifestyle-related diseases requiring long-term treatment and stress diagnosis, as well as primary care.」

「In the specimen testing equipment field, we also continued to focus on expanding sales of the latest GASTAT-700Model blood gas analyser.」

「Against this backdrop, and from the standpoint of healthcare financing and QOL, the Company will continue to focus on research and development of specimen testing equipment and healthcare products that are less affected by reimbursement rates, to enable self-care for lifestyle-related diseases requiring long-term treatment and stress diagnosis, as well as primary care.」

「For specimen testing equipment, the Company will continue to focus on selling various value-added analyzers, including blood gas analyzers, that are less affected by reimbursement rates.」

「From the standpoint of healthcare financing and QOL, the Company will continue to focus on research and development in the POCT (Note 4) field, including specimen testing equipment and healthcare products with added value that are less affected by reimbursement rates, to enable self-care for lifestyle-related diseases requiring long-term treatment and stress diagnosis, as well as primary care.」